ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Elderly Men Say Physicians Are Recommending PSA Tests

December 26, 2003

Low-Income Women Lack Mammography Access: Survey

May 14, 1993

NCAB Agrees With NCI Recommendation To Drop PO1 Chartered Committees, Adopt Single Review

February 13, 1987

Darbepoetin Didn’t Decrease Blood Transfusions, Lowered Overall Survival, Study Finds

April 27, 2007

DCPTC Proceeding With Plans For Intramural Lab

January 30, 1987

NSABP Trial Finds Raloxifene Equivalent To Tamoxifen For Cancer Risk Reduction

April 28, 2006